The vast overexpression of Trop-2 in main cancer types, e.g. breast (76%), stomach (70%), prostate (80%), pancreas (83%), cervix (91%) cancers (23), indicates that these mutagenic and non-mutagenic signatures are candidate to frequently interact in cancer cells (1). Here, TACSTD2 is linked to cancer.